#1 Clinical Trials Search in Europe

Metyrapone

Metyrapone is a medication being studied in clinical trials for its potential benefits in treating several medical conditions. This article explores the ongoing research on metyrapone’s effects in disorders like Cushing’s syndrome, depression, and metabolic issues. We’ll examine how this drug works and what scientists hope to learn from these studies.

Table of Contents

What is Metyrapone?

Metyrapone, also known by its brand name Metopirone, is a medication that affects the production of cortisol in your body[1]. Cortisol is often called the “stress hormone” because it helps your body respond to stress. However, too much cortisol can lead to various health problems.

This drug is approved by the U.S. Food and Drug Administration (FDA) for diagnosing adrenal insufficiency, a condition where your body doesn’t produce enough cortisol[2]. In Europe, it’s also approved for treating a condition called Cushing’s syndrome, which involves having too much cortisol in your body[3].

How Metyrapone Works

Metyrapone works by blocking an enzyme in your body called 11β-hydroxylase. This enzyme is important in the final step of cortisol production. By inhibiting this enzyme, metyrapone reduces the amount of cortisol your body produces[4].

In addition to lowering cortisol, metyrapone can also affect other hormones in your body. It may increase the levels of hormones that come before cortisol in the production process, such as 11-deoxycortisol[5].

Conditions Treated with Metyrapone

Metyrapone is used or being studied for several conditions related to cortisol imbalance:

  • Cushing’s Syndrome: This is a condition where your body produces too much cortisol. Metyrapone can help lower cortisol levels in these patients[3].
  • Mild Autonomous Cortisol Secretion (MACS): This is a milder form of cortisol excess. Research is ongoing to see if metyrapone can help control symptoms in these patients[2].
  • Depression: Some studies are looking at whether metyrapone, when added to regular antidepressant treatment, might help improve symptoms in people with depression who haven’t responded well to standard treatments[4][5].
  • Metabolic Syndrome and Obesity: Researchers are investigating whether short-term use of metyrapone might improve how the body responds to sugar intake in people with metabolic syndrome and obesity[6].

Dosage and Administration

The dosage and how you take metyrapone can vary depending on why you’re using it. Here are some examples from clinical studies:

  • For Cushing’s Syndrome: Doses may range from 250 mg to 6000 mg per day, taken orally in divided doses[3].
  • For research in depression: Some studies have used 500 mg twice daily for 3 weeks[7].
  • For research in metabolic syndrome: A study used 15 mg per kilogram of body weight, given twice over 12 hours[6].

Always follow your doctor’s instructions on how to take metyrapone. Never adjust your dose without consulting your healthcare provider.

Potential Side Effects

Like all medications, metyrapone can cause side effects. Some potential side effects may include:

  • Nausea or vomiting
  • Dizziness or lightheadedness
  • Headache
  • Abdominal pain
  • Changes in blood pressure

In some cases, metyrapone might lower cortisol levels too much, leading to symptoms of adrenal insufficiency. These could include fatigue, weakness, and dizziness. If you experience these symptoms, contact your doctor immediately[2].

Ongoing Research and Future Applications

Researchers are exploring new ways metyrapone might be used to help patients:

  • Depression Treatment: Studies are looking at whether adding metyrapone to standard antidepressants might help people with depression who haven’t responded well to usual treatments[4][5].
  • Addiction Treatment: Some research is investigating whether metyrapone, possibly in combination with other drugs, might help in treating addictions like cocaine use disorder or tobacco use disorder[1].
  • Metabolic Health: Scientists are studying whether short-term use of metyrapone might improve how the body handles sugar in people with metabolic syndrome and obesity[6].

It’s important to note that these are areas of ongoing research. Metyrapone is not currently approved for these uses, and more studies are needed to determine if it might be helpful in these conditions.

Condition Study Focus Key Outcomes Measured
Cushing’s syndrome Efficacy and safety of metyrapone in normalizing cortisol levels Urinary free cortisol levels, clinical symptoms
Depression Metyrapone as an augmentation to antidepressant therapy Depression scores, cortisol levels, onset of action
Metabolic syndrome Effects on sympathetic nervous system and insulin sensitivity Nervous system response to food intake, insulin sensitivity
Substance use disorders Potential for treating cocaine and tobacco dependence Safety, craving reduction, addiction measures
Mild Autonomous Cortisol Secretion Safety and efficacy in controlling cortisol-related symptoms Blood pressure, glucose levels, lipid profile, adverse events

FAQ

  • What is metyrapone and how does it work? Metyrapone is a medication that blocks the production of cortisol, a stress hormone, in the body. It works by inhibiting an enzyme called 11β-hydroxylase, which is involved in cortisol synthesis.
  • What conditions are being studied with metyrapone? Clinical trials are investigating metyrapone for various conditions, including Cushing's syndrome, depression, metabolic syndrome, and as a potential treatment for cocaine and tobacco use disorders.
  • How is metyrapone administered in these trials? In most trials, metyrapone is given orally in capsule form. The dosage and frequency vary depending on the study and condition being treated.
  • What are the potential side effects of metyrapone? While side effects can vary, some trials are specifically monitoring for changes in blood pressure, electrolyte levels, and adrenal function. Always consult with a healthcare provider about potential risks.
  • How long do these clinical trials typically last? The duration of metyrapone trials varies widely, ranging from a few weeks to several months. Some studies include follow-up periods to assess long-term effects and safety.

Ongoing Clinical Trials on Metyrapone

  • Study on the Effect of Metyrapone on Heart Health in Patients with Adrenal Tumors and Mild Cushing’s Syndrome

    Recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study on Metyrapone for Patients with Mild Autonomous Cortisol Secretion

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Cushing's syndrome: A disorder caused by prolonged exposure to high levels of cortisol in the body, leading to various symptoms such as weight gain, high blood pressure, and muscle weakness.
  • Cortisol: A hormone produced by the adrenal glands that plays a role in stress response, metabolism, and immune function.
  • Hypothalamic-Pituitary-Adrenal (HPA) axis: A complex set of interactions between the hypothalamus, pituitary gland, and adrenal glands that regulates many body processes, including stress response and cortisol production.
  • Metabolic syndrome: A cluster of conditions that occur together, increasing the risk of heart disease, stroke, and type 2 diabetes. These conditions include high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels.
  • Adrenal insufficiency: A condition in which the adrenal glands do not produce enough of certain hormones, particularly cortisol.
  • Dexamethasone Suppression Test (DST): A test used to assess the function of the adrenal glands and their response to a synthetic corticosteroid called dexamethasone.
  • Urinary Free Cortisol (UFC): A measure of cortisol levels in urine, used to diagnose and monitor conditions related to cortisol production.

References

  1. https://clinicaltrials.gov/study/NCT02406066
  2. https://clinicaltrials.gov/study/NCT06106295
  3. https://clinicaltrials.gov/study/NCT02297945
  4. https://clinicaltrials.gov/study/NCT03491696
  5. https://clinicaltrials.gov/study/NCT00125554
  6. https://clinicaltrials.gov/study/NCT01620684
  7. https://clinicaltrials.gov/study/NCT01375920